These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 17350323

  • 1. Recent advances in the treatment of salivary gland cancers: emphasis on molecular targeted therapy.
    Milano A, Longo F, Basile M, Iaffaioli RV, Caponigro F.
    Oral Oncol; 2007 Sep; 43(8):729-34. PubMed ID: 17350323
    [Abstract] [Full Text] [Related]

  • 2. Salivary gland malignancies: the role for chemotherapy and molecular targeted agents.
    Surakanti SG, Agulnik M.
    Semin Oncol; 2008 Jun; 35(3):309-19. PubMed ID: 18544445
    [Abstract] [Full Text] [Related]

  • 3. Basic evidence of molecular targeted therapy for oral cancer and salivary gland cancer.
    Hamakawa H, Nakashiro K, Sumida T, Shintani S, Myers JN, Takes RP, Rinaldo A, Ferlito A.
    Head Neck; 2008 Jun; 30(6):800-9. PubMed ID: 18429007
    [Abstract] [Full Text] [Related]

  • 4. Molecular mechanisms of signal transduction: epidermal growth factor receptor family, vascular endothelial growth factor family, Kit, platelet-derived growth factor receptor, Ras.
    Erman M.
    J BUON; 2007 Sep; 12 Suppl 1():S83-94. PubMed ID: 17935283
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications.
    Tortora G, Ciardiello F, Gasparini G.
    Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498
    [Abstract] [Full Text] [Related]

  • 11. Molecularly targeted therapies in advanced gastric cancer.
    Janjigian YY, Shah MA.
    Minerva Gastroenterol Dietol; 2011 Mar; 57(1):75-88. PubMed ID: 21372772
    [Abstract] [Full Text] [Related]

  • 12. ErbB-directed immunotherapy: antibodies in current practice and promising new agents.
    Friedländer E, Barok M, Szöllosi J, Vereb G.
    Immunol Lett; 2008 Mar 15; 116(2):126-40. PubMed ID: 18201769
    [Abstract] [Full Text] [Related]

  • 13. An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents.
    Agulnik M, Siu LL.
    Curr Med Chem Anticancer Agents; 2004 Nov 15; 4(6):543-51. PubMed ID: 15579019
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Molecular targeting in the treatment of either advanced or metastatic bladder cancer or both according to the signalling pathways.
    Wallerand H, Reiter RR, Ravaud A.
    Curr Opin Urol; 2008 Sep 15; 18(5):524-32. PubMed ID: 18670279
    [Abstract] [Full Text] [Related]

  • 19. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents.
    Tabernero J.
    Mol Cancer Res; 2007 Mar 15; 5(3):203-20. PubMed ID: 17374728
    [Abstract] [Full Text] [Related]

  • 20. Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era.
    Wagner AD, Moehler M.
    Curr Opin Oncol; 2009 Jul 15; 21(4):381-5. PubMed ID: 19412098
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.